Clinuvel Pharmaceuticals
Mr Hay is General Manager of CLINUVEL’s European office, focused on the roll out of CLINUVEL’s drug SCENESSE® (afamelanotide 16mg) in Europe for the treatment of adult patients with the ultra-orphan disorder erythropoietic protoporphyria (EPP). He has over a decade of diverse experience with the CLINUVEL Group, having held communications and operations positions in Australia, Switzerland and Europe.
Mr Hay has previously held marketing communications roles in the not-for-profit sector in Australia. He holds a BA (Media & Communications) from the University of Melbourne, Australia, and a MA (International Relations) from the Freie Universität Berlin, Germany.
This person is not in any offices
Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population.